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Abstract: Melanoma is one of the most severe public health issues worldwide, not only 
because of the high number of cases but also for its poor prognosis in late stages. Therefore, 
early diagnosis and efficient treatment are key toward a future solution. However, melanoma 
is highly resistant to cytotoxicity in its metastatic form. In this context, we propose a 
therapeutic strategy based on a targeted chemo-photothermal nanotransporter for cytotoxic 
compounds. This approach comprises the use of core-multishell gold nanorods, coated with 
mesoporous silica and further covered with a thermosensitive polymer, which is vectorized 
for selective internalization in melanoma cells. The proposed nanoformulation is capable of 
releasing the transported cytotoxic compounds on demand, in response to near-IR irradiation, 
with high selectivity and efficacy against malignant cells, even at low concentrations, thereby 
providing a new tool against melanoma disease. 
1. Introduction 
Melanoma is one of the most severe public health issues worldwide, as indicated by the yearly 
increasing number of cases.[1] Although early diagnosed melanoma is usually treated by 
Complete Manuscript
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radical surgery, conversely, at metastatic malignant late states it has a poor prognosis.[2] 
Indeed, melanoma has been named as one type of tumor with the highest metastatic 
potential.[3] Currently, only dacarbazine as a single agent and bolus interleukin-2 as an 
immunotherapy alternative, have been approved by the FDA (Food and Drug Administration) 
as selective treatments for malignant melanoma with poor prognosis. This deficient situation 
has stimulated the scientific community to find novel strategies for early diagnosis and 
efficient treatment.  
Early diagnosis is one of the keys toward reducing the risks of this malignant disease. 
Nowadays, the development of new synthetic strategies for radiolabeled targeting agents has 
afforded new diagnostic systems based on the melanoma overexpression of the melanocortin-
1 receptor (MC1R). MC1R is a G-protein localized in the cell membrane, linked to skin 
pigmentation, which has avidity for the alpha-melanocyte stimulating hormone (α-MSH). 
Peptide emulations of this hormone, both linear[4] and circular[5] derivatives, named 
NAPamide, have been extensively used as vectorization moieties for imaging, leading to a 
significant improvement in early diagnosis.[6]   Mechanism is based on the alpha melanocyte 
recognition with this receptor. MCR-1 is present in the cell wall and binds with the peptide 
that emulates the specific spot of interaction of the alpha melanocyte. 
On the other hand, melanoma is also considered a malignant and refractory tumor in its 
metastatic form, highly resistant to cytotoxic agents. On account of their intrinsic and 
acquired properties, melanocytes have developed resistance against apoptosis. The classical 
treatment for most solid tumors based on the systemic administration of cytotoxic drugs, 
immunotherapy and cocktail combinations, usually effective against other tumors in classic 
chemotherapy,[7] result almost useless against melanoma.[8],[9],[10]  
As a representative example, Doxorubicin (DOX) administration, because of its multiple 
modes of action, is one of the most relevant treatments for multiple cancerous diseases. 
However, melanoma is naturally resistant to its effect through the protection of the 
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mitochondrial DNA system[8] active in these cells, and systemic treatments result almost 
ineffective. Treatment with DOX, even at high doses, would only lead to an increase of multi-
resistance and important side effects for the patient.  
The possibility of improving the performance of DOX for the treatment of melanoma, 
whether metastatic or primary, has been recently studied, involving the combination of this 
drug with immunotherapy, vectorized conjugates and other approaches.[11],[12] 
Alternatively, nanomedicine may offer promising alternatives for such extreme cases. The 
passive targeting, known as Enhanced Permeability and Retention (EPR) effect, results in 
nanometer-sized objects passively accumulating within tumoral mass, as a consequence of the 
highly porous blood vessels that irrigate the malignant tissue.[13–15] This effect has been 
exploited to deliver cytotoxic drugs to tumor cells in a selective manner, via encapsulation 
within nanometric carriers. In the case of DOX, previous works have reported the higher 
cytotoxic efficacy employing nanoformulations, as compared to classic chemotherapy in 
melanoma tumors.[12],[16] The increased tumor cell mortality achieved with nanocarriers can be 
associated with the significantly higher local concentration of DOX that can be achieved 
inside melanoma cells, which allows a decrease of the administered doses, thereby reducing 
the usually severe side effects. 
On the other hand, photothermal therapy (PTT) is attracting great attention as a minimally 
invasive treatment for cancer therapy.[17–19] This therapy is based on the conversion of light 
into localized heating, mediated the strong absorption of certain nanoparticles.[20–22] This is 
particularly effective in the near infrared (NIR) spectral range between 650-900 nm, known as 
the first biological window. In this region the penetration of light in tissues is higher due to 
reduced absorption and scattering, which also results in marginal tissue damage.[23] 
Nanomaterials such as gold nanorods, gold nanoshells, gold nanocages, gold nanostars, 
graphene and carbon nanotubes, have been extensively studied for light-induced local heating, 
because of their ability to efficiently absorb NIR radiation and release it as heat.[24–27] 
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PPT using a NIR laser has however two main limitations: the penetration depth of the laser[28] 
and the amount of NIR-responsive nanoparticles that can be accumulated inside the tumor, 
which determines the local heating efficiency. NIR penetration depends on the specific type 
of tissue and the power of the irradiation source, but in any case it is limited to a few 
centimeters in the best cases.[29] Thus, PPT is only suitable for treatment of superficial cancers 
such as melanoma, uveal or even laser accessible cancers such as cervix or colon. One of the 
most popular types of nanocrystals for PTT are gold nanorods (GNRs).[30] GNRs have 
attractive optical properties related to localized surface plasmon resonances (LSPR), in 
particular the most intense longitudinal LSPR in the NIR, which can be tuned by the GNR 
dimensions, through the synthesis procedure.[31] GNRs show excellent photothermal 
conversion effects and generate localized hyperthermia.[21,27] The clinical application of GNRs 
in PTT has however been limited due to the cytotoxicity caused by the remaining surfactant 
cetyltrimethylammonium bromide (CTAB), which is typically used for GNR synthesis. In 
previous works, this problem has been solved by encapsulating the GNRs with polyethylene 
glycol (PEG),[32] or with mesoporous silica shells (GNR@MS).[33,34] GNR@MS nanoparticles 
are of particular interest, due to the properties of the mesoporous silica layer, which can not 
only reduce the cytotoxicity and the aggregation of GNRs, but also improve the drug-loading 
ability. In addition, mesoporous silica can be easily modified by introducing different 
functional groups, which act as anchoring points for subsequent surface modification with 
functional biomolecules. In Vallet-Regí’s group, mesoporous silica nanoparticles have been 
studied as controlled drug delivery systems,[35,36] and more recently core@shell 
magnetite@mesoporous silica with a polymer surface coating were used as heating/stimuli-
response drug delivery systems.[37] This polymeric coating exhibited a linear-to-globular 
transition at temperatures above 42-43 oC, thereby allowing the release of drugs encapsulated 
inside the mesoporous silica channels.[38]  
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Scheme 1.  Representation of a photoresponsive nanocarrier with surface anchored 
NAPamide targeting (PR-NC-NAP), which is proposed for melanoma treatment. 
 
We present herein a strategy for melanoma treatment, based on core-shell GNR@MS covered 
with a thermosensitive polymeric shell capable of both releasing on demand the transported 
cytotoxic compounds, in response to NIR illumination, and selectively recognizing melanoma 
cells. (Scheme 1) The selectivity is provided by the external decoration of the polymer shell 
with NAPamide, which is expected to enhance the internalization of the drug nanocarrier 
inside the melanoma cancer cells, even in the presence of healthy cells. This system shows a 
selective capacity to destroy tumor cells by triggering drug release only when NIR light is 
applied, exploiting the synergic effect between the cytotoxic drug and the local temperature 
increase caused by the photothermal effect.[34,39,40, 41,42,43] This design provides a means to 
achieve a higher therapeutic efficacy while minimizing the administered drug dose. 
2. Results and discussion 
The first step for the construction of the “smart” nanovehicles comprised the synthesis of 
GNRs. To this aim, a modified seed-mediated growth method in aqueous solution was used, 
as described in the experimental section. Figure 1A shows a representative TEM micrograph 
of the obtained GNRs, where the monodispersity of the sample can be appreciated. The GNRs 
featured average length, width and aspect ratio of 43±4 nm, 10±3 nm and 3.9±0.3, 
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respectively. The extinction spectrum of GNRs is provided in Figure S2 (Supporting 
Information), displaying an intense absorbance around 808 nm due the longitudinal LSPR 
(max 766 nm for bare rods, 796 after silica coating). After synthesis, GNRs were washed by 
centrifugation to remove excess reactants and coated with mesoporous silica. 
 
Figure 1: Representative transmission electron micrographs of GNR (a), GNR@MS (b) PR-
NC (c) and PR-NC-NAP (d). The insets provide higher magnification images. 
 
Mesoporous silica encapsulation (GNRs@MS) was carried out using a recently reported 
method based on a CTAB-templated sol-gel process that yielded mesoporous silica shells 
with radial pores (average diameter 2.1 nm) upon CTAB removal.[33] Representative TEM 
images of the silica coated GNRs are displayed in Figure 1B and in Figure S1 (Supporting 
Information), showing homogenous coating of individual GNRs, with no sign of aggregation. 
GNR@MS were then washed by centrifugation to remove small silica nanoparticles formed 
by TEOS condensation.  
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To avoid silica degradation in water,[44] the colloidal particles were re-dispersed in ethanol. 
Prior to the polymerization of pNIPAM/NHMA around the nanoparticles, it is necessary to 
introduce polymerizable groups onto the silica surface. For this purpose, and with the aim to 
functionalize only the nanoparticle surface, GNR@MS were treated with 3-
[tris(trimethylsiloxy)silyl]propyl methacrylate (MPS) prior to surfactant extraction, following 
a reported method.[38] After this step, the CTAB template was removed by ionic exchange 
employing a solution of NH4NO3, to prevent the degradation of the new moiety (MPS). Once 
the particles are free of surfactant inside the silica channels, polymer coating was performed 
by radical polymerization, employing a monomer feed NIPAM/NHMA/MBA molar ratio of 
0.85/0.10/0.05. This composition was established to obtain a lower critical solution 
temperature (LCST) at 42-43 oC.[38] Figure 1C shows representative TEM images of PR-NC, 
where the polymer shell is observed as a dark coating around the particles, because 
phosphotungstic acid staining was applied to enhance the contrast of the organic shell. 
Selectivity against melanoma cells was obtained by choosing the peptide NAPamide as the 
targeting moiety. NAPamide was thus synthetized with protected amine and acid groups 
within the main chain (Scheme 2).  
 Scheme 2. a) Solid phase NAPamide synthesis, b) NAPamide PEGylation and coating over 
polymer surface on the PR-NC. 
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This methodology leaves only one amino nucleophilic active site localized in the lysine rest 
chain for the PEGylation process. The employed di-acid PEG ((NHS)2PEG (2000 g/mol)) 
previously activated by NHS, enables the selective condensation of the free amino group with 
one of the acid groups of the PEG chain, even in the presence of the non-activated acid group 
from the aspartic acid in the initial peptide. Additionally, the absence of a base until the last 
step minimizes the aspartimide problem, which is very common in peptide sinthesys.[45] 
PEG/peptide condensation was carried out with a 1:1 ratio, preventing formation of the bis-
adduct and leaving the acid group at the end of the PEG chain for subsequent Steglich 
esterification[46] with the available primary alcohol groups from the NHMA monomer in the 
polymer coating. Finally, an Fmoc deprotection step was carried out over the peptide-
functionalized PR-NC, under mild conditions. 
The nanoparticles were characterized by TEM, Z-potential, DLS, FTIR and TGA. FTIR was 
used to verify the successful functionalization of GNR@MS with MPS and further with the 
NIPAM/NHMA polymer, Figure S3. The spectra present a characteristic peak at 1100 cm-1 
assigned to the Si–O vibration of silica. When the mesoporous silica nanoparticles were 
successfully functionalized with MPS, two characteristic peaks appeared at 1633 and 1702 
cm-1 (C=O stretching). Upon deposition of the pNIPAM/NHMA polymer shell on the 
nanoparticles, these two peaks are hidden by three new bands due to the formation of a 
secondary amide (C=O stretching 1637 and 1532 cm-1) and the deformation of methyl groups 
on –C(CH3)2 (1460 cm-1), which is in accordance with previous pNIPAM/NHMA 
functionalizations.[38] Unfortunately, functionalization of the nanoparticles with NAPAmide 
did not lead to any variations in the FTIR spectra as expected, owing to the low amount that 
the targeting moiety represents as compared to the polymer bands, and the peptide bands 
being present within the same IR spectral region. Additionally, Z-potential measurements 
provided an estimate of the variation in surface charge during the functionalization process. 
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The Z-potential was found to vary from -14.4 mV for GNRs coated with silica (GNR@MS) 
to -21.6 mV when the polymer layer was grown on the surface. NAPamide anchoring on the 
polymer layer resulted in a very low surface charge (Z-Pot= -2.27 mV). TGA was also 
performed at all steps to confirm the successful functionalization of the nanoparticles and 
extraction of the surfactant. The final amount of polymer coating was determined as 36.45% 
of the total mass loss. (S.I. Figures S4 and S5.) 
The amount of heat produced upon NIR irradiation depends on the NIR laser power and the 
concentration of nanoheaters, as well as on the irradiation time. It is well known that efficient 
hyperthermal therapy requires the local temperature to reach at least 43 oC,[17] at which 
protein denaturation and disruption of the cellular membrane would occur, leading to tumor 
tissue ablation. Studies at different particle concentrations were performed, from 10 µg/mL to 
100 µg/mL. Different laser power densities were also tested to achieve the target temperature 
with the lowest possible power density, and to reduce residual side effects of NIR radiation. 
Additionally, exposure times of 5, 10 and 15 minutes were tested toward reaching the 
hyperthermia temperature in the shortest time possible. As described in Table S2 of the 
Supporting Information, a hyperthermia macroscopic temperature required a concentration of 
nanoheaters of 50 g/mL, 1 W/cm2 NIR laser power density and 10 minutes of exposition 
time.  
Drug loading and release capacities of the nanocarriers were tested using fluorescein as a 
model drug molecule. The mesoporous material PR-NC was incubated overnight under 
magnetic stirring at 50 oC in a saturated solution of fluorescein. The nanocarriers were then 
washed by centrifugation until the supernatant was clear, and subsequently dried in a vacuum 
oven at 30 oC. The fluorescein release experiments were performed by placing a dispersion of 
fluorescein-loaded nanocarriers (1 mg/mL) in a transwell permeable support in PBS. The 
different transwell plates were placed in two different ovens at 37 and 50 oC. An additional 
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transwell plate was placed in an oven at 37 oC and irradiated with a NIR laser at 0.5 W/cm2 
for 10 minutes each hour. The PBS medium was measured by fluorescence spectroscopy and 
replaced every hour to estimate the amount of released fluorescein. As shown in Figure 2, 
fluorescein release was significantly enhanced under NIR laser irradiation, as compared to its 
counterpart in an incubator at 50 0C.  
These results are in accordance with the existing literature,[38] where higher fluorescein 
release was achieved when heat was first produced at the nanoscale. In the case of magnetic 
hyperthermia, two effects have been described with PR-NC: (1) the collapse of the 
thermosensitive polymer structure leads to opening of the mesoporous silica pores, and (2) 
enhanced diffusion of fluorescein from the pores when the temperature was increased.[38] 
Although fluorescein leaking was observed at 37 oC, it should be taken into consideration that 
the polymer coating acts as a diffusion barrier around the nanoparticle and fluorescein release 
is forced by the continuous replacement of the incubation media (PBS). Heating temperatures 
optimization of the material is shown on Table S2 in Supporting information. 
).  
Figure 2: Responsive fluorescein release profile over time (24h) at 37 oC and 50 oC, and with 
NIR laser irradiation (1W, 10 min) for fluorescein loaded PR-NC. 
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In order to study the effect of the grafted NAPAmide targeting agent, FF_C108, a fibroblast 
healthy cell line from foreskin as control, and #17 melanoma cancer cells were seeded to 
carry out in vitro cellular uptake tests. Cell internalization was monitored by fluorescence 
microscopy (Figure 3a) and flow cytometry (Figure 3b), with tagged NCF-NAP and NCF. 
For this purpose, fluorescent mesoporous silica nanoparticles without metal cores were 
prepared as described in the experimental section. 
For uptake experiments, a concentration of 75 µg/mL of NCF-NAP and NCF was used for 
both cell  lines and both materials. The cell cultures were incubated for 24 hours and uptake 
was evaluated by flow cytometry measuring FITC percentage (Figure 3b), which represents 
the percentage of cells that had engulfed nanoparticles. Figure 3a,b shows that NCF 
nanoparticles did not internalize into either fibroblast or melanoma cells, which was expected 
due the negative surface charge of these nanoparticles. However, the presence of NAPAmide 
at the polymer surface promotes internalization of the NCF-NAP particles by both cell lines. 
Our data clearly show that internalization in melanoma is higher (25%) than in the fibroblast 
healthy cell line, pointing toward a ligand–receptor mediated process besides the charge 
induction effect. As can be rationalized from the experiments, the uptake by melanoma cancer 
cells is higher than that for healthy cells, due to overexpression of NAPamide receptors on the 
melanoma cell wall. 
In order to probe this differentiation in the internalization results from NAPamide interaction, 
a further experiment was performed to study cell uptake with different concentrations of 
NCF-NAP. Figure 4 reveals that, in the best case (100 µg/mL), nanoparticle uptake by 
fibroblasts is almost 3 times lower than that by melanoma cancer cells. This difference 
however decreases when increasing the concentration of the targeted particles, due to receptor 
saturation, which allows us to conclude that the internalization process is concentration-
dependent. 
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Figure 3: A) Optical microscopy images for both cell lines (#17 skin cancer cells and 
fibroblast FFC_C108) incubated with 75g/mL, for 2 hours, using NCF and NCF-NAP. Bar: 
200 µm B) Cell uptake at 75 g/mL, for 2 h, using NCF-NAP and NCF. 
 
Figure 4: Dose-dependent cell uptake of NCF-NAP, for FF_C108, fibroblasts (control) and 
#17 melanoma cancer cells. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
13 
 
 
Figure 5. Optical microscopy images for cells incubated with 50g/mL of PR-NC-NAP and 
DOX-loaded PR-NC-NAP, with and without NIR irradiation. Bar 200 µm. 
 
The final nanoparticle concentration in melanoma cancer cells appears to be higher than in 
fibroblasts at low concentrations, making more effective the potential synergy between 
chemo- and photo-thermal therapies, induced by the nanocarrier. To verify the synergistic 
effect of the treatment, the targeted nanocarrier was loaded with doxorubicin and tested in cell 
viability assays, as described in the experimental section. The same cell lines used for 
internalization experiments, i.e. FF_C108 (healthy fibroblast) and #17 (melanoma cancer 
cells), were employed, keeping in all experiments n=3. It is worth mentioning that 
nanoparticles and cells were incubated for 2 hours, and then the cells were washed with PBS 
twice to remove non-internalized nanoparticles. Cytotoxicity was tested using alamarBlue® 
assay, 24 hours after irradiation.  
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Figure 5 illustrates the cell viability of both cell lines treated with 50 g/mL blank 
nanoparticles (free of DOX) and DOX-loaded nanoparticles. (For more information, see 
Figure S10) As expected, both cell lines maintain high viability values in the presence of 
unloaded nanocarriers, without NIR application. For melanoma cancer cells the viability 
decreases dramatically (up to 13%) when DOX- loaded nanoparticles are present in the 
culture medium. This effect can be attributed to the higher internalization of the nanoparticles 
in melanoma cancer cells and spontaneous DOX release. On the other hand, fibroblast cell 
viability was 72%, mainly due to lower nanocarrier uptake, added to the better defense 
mechanisms that healthy cells present against chemotherapeutics.[47] The same experiment 
groups (control, blank PR-NCF-NAP and DOX-loaded PR-NCF-NAP) with both cell lines, 
were irradiated with NIR light (808 nm, 1 W/cm2) for 10 minutes, monitoring the temperature 
with a fluorooptic probe (this irradiation set up was fixed for every subsequent experiment). 
As can be observed, the viability controls were not affected by laser exposure. In the case of 
blank nanocarriers, a macroscopic temperature of 41 0C was reached after irradiation and a 
55% decrease in cell viability was achieved only for melanoma cancer cells. Meanwhile, for 
fibroblasts cell viability was almost the same as for the nanoparticles control without NIR 
irradiation (77%).  
We then studied the combined action of chemo and PPT effects, by incubating cells with 
DOX loaded PR-NCF-NAP and irradiating with the NIR laser. We found an extraordinary 
increase of cell death for melanoma cancer cells, down to 1% viability, whereas viability of 
the healthy cell line remains close to that of the DOX-loaded photoresponsive nanocarriers 
control (73%). These findings are again related to the enhanced nanocarrier uptake by 
melanoma cancer cells. Higher internalization rates lead to a higher concentration of both 
gold nanorods and drug inside the cells, resulting in a heat shock which effectively provokes 
cancer cell death by itself. In addition, the decrease in melanoma cell viability with the 
combined treatment (DOX+NIR laser) reveals that drug release is allowed through polymer 
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shrinkage, induced by the temperature rise inside living cells under NIR laser irradiation. On 
the other hand, it has been described in the literature that the cytotoxicity of DOX can be 
enhanced at higher temperature, thereby improving the cytotoxicity of the loaded drug.[48,49]  
As discussed above, the thermosensitive polymer coating responds to temperature changes 
within the hyperthermia range. An additional important aspect about the heating mechanism 
should also be evaluated; namely, whether the temperature increment must be macroscopic in 
order to trigger the polymer transition or whether the local heating in close vicinity to the 
GNRs is sufficient to induce the polymer transition and pore opening. This “hot-spot” effect 
comprises a local heating when the gold nanorods are irradiated with a NIR laser, without 
reaching a macroscopic hyperthermia temperature. The presence of this effect in thermo-
responsive materials allows the use of low nanoparticle doses because it is not necessary to 
increase the temperature all over the tissue to trigger drug release and subsequent cell death.  
In order to test if the cytotoxic effect can be achieved without a macroscopic temperature rise, 
the concentration of nanoparticles was decreased by 5-fold and 10-fold, to prevent overall 
heating of the cell cultures. The macroscopic temperature after irradiation was monitored 
during the experiments, being ca. 38 0C in all cases. Figure 6 shows the viability of both cell 
lines treated with low doses, (5 and 10 g/mL) of blank and DOX-loaded PR-NC-NAP, as 
well as with and without NIR irradiation. As expected, both cell lines incubated with drug-
free nanocarriers maintained a similar high viability as that of the controls without NIR 
irradiation. However, the cell viability of melanoma cancer cells exposed to 5 and 10 g/mL 
significantly decreases (60 and 41%, respectively) when DOX-loaded PR-NC-NAP were used. 
On the contrary, the fibroblasts were only affected by the DOX-loaded nanoparticles at the 
higher dose (10 g/mL). In the same cellular assay, both cell lines were irradiated with NIR 
light (808 nm), observing 15% melanoma cell viability at higher doses and almost no cell 
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death at the lower dose. It is also remarkable that the cell viability of fibroblasts is the same as 
that for non-irradiated cells exposed to the blank nanocarriers (100%).  
 
Figure 6: Cell viability at different nanocarrier concentrations, 10 g/mL (A) and 5 g/mL 
(B), for healthy fibroblasts and melanoma cancer cells. 
 
When the melanoma cancer cells were incubated with DOX-loaded nanoparticles and 
irradiated with NIR laser, the viability of melanoma cells fell down to 24%, in the case of 
cells treated with 10 g/mL, while at 5 g/mL the viability decrease was less pronounced but 
still noticeable. This is a clear evidence of the synergistic effect of PTT and chemotherapy, at 
low nanoparticle dose. Again, the healthy fibroblasts were not affected by the DOX loaded 
nanocarriers treatment, even under NIR irradiation, at both concentrations. The treatment with 
DOX and NIR laser at low dose also shows that the viability of melanoma cells was the same, 
with or without laser irradiation. This could mean that the thermal effect is no longer enough 
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to overcome the cancer cell countermeasures. Even though the thermal effect is lost at very 
low concentrations, the chemotherapy treatment is still working, probably due to doxorubicin 
delivery mediated by NAPAmide targeting.  
We finally explored the possibility to enhance cell death by multiple irradiations. Melanoma 
cancer cells were incubated as in previous assays, with 5 g/mL of the final PR-NC-NAP 
(with and without DOX). Every 24h the cells were irradiated with NIR laser (808 nm) for 10 
minutes at 1W/cm2. Cell viability was evaluated by alamarBlue® assay, 24h after irradiation. 
As the viability assay is biocompatible, the culture medium of each sample was maintained 
during the test and replaced again at the end of the assay. As shown in Figure S11, cell 
viability was almost the same after 2 and 3 NIR-laser irradiations. This result is in agreement 
with the drug release experiment, where we found that after one irradiation almost half of the 
cargo was released, so a single NIR irradiation is sufficient to achieve the desired therapeutic 
effect.  
3. Conclusion 
In summary, multifunctional PR-NC-NAP composite nanoparticles were synthesized via 
radical polymerization onto GNR@MS hybrid nanoparticles. The nanoparticles demonstrated 
thermal/NIR laser sensitivity and outstanding photothermal conversion. The NAPamide 
peptide was demonstrated to be an excellent targeting ligand for melanoma cancer cells, as it 
could discriminate healthy cells of human fibroblast foreskin from metastatic ones. The 
viability of cancer cells treated with DOX-loaded nanocarriers was significantly reduced at 
relatively low nanoparticle concentration (10 g/mL) and short NIR laser irradiation time (10 
minutes). Thus, DOX-loaded nanoparticles exhibited high cytotoxicity as compared with 
chemotherapy or PTT alone, due to a synergistic effect between chemo and PTT, where NIR 
light acts as a trigger to induce DOX release from the nanoparticles through the temperature 
increase inside the cells, causing cell death. Our results demonstrate the feasibility of such 
nanocarriers to be a powerful instrument for drug delivery systems, in response to 
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thermal/NIR laser irradiation, for melanoma cancer cells, on account of the discrimination 
between cancerous and healthy cells present in tumors. Our nanocarriers could be exploited as 
a combined chemo-PTT system, with improved therapeutic efficacy even at low drug dose for 
superficial tumors, being a promising candidate for “in vivo” evaluation. 
 
4. Experimental Section 
Materials  
Amino-protected Fmoc aminoacids, piperidine, N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-
1-yl)uronium hexafluorophosphate, O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU), 1-Hydroxybenzotriazole hydrate (HOBT), Diisopropyl Ethyl 
amine (DIPEA), Trifluoroacetic acid (TFA), Triisopropyl silane (TIPS), O,O′-Bis[2-(N-
Succinimidyl-succinylamino)ethyl]polyethylene glycol 2KDa, Rink amide resin, Sephadex G-
25, as well as the solvents used in the condensation, deprotection and release stages, such as 
N’,N’-dimethylformamide (DMF) and dichloromethane (DCM), gold chloride trihydrate 
(HAuCl4.3H2O), ammonium nitrate (NaNO3), Sodium carbonate (Na2CO3), 
cetyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), 
amminopropyltriethoxysilane (APTES), 3-(trimethoxysilyl)propyl methacrylate (MPS), as 
well as the reagents for polymerization, N-isopropylacrylamide (NIPAM,≥99%), N-
(hydroxymethyl)acrylamide solution (NHMA, 48 wt % in H2O), N,N′-
methylenebis(acrylamide) (MBA, 99%), ammonium persulfate (APS), and fluorescein 
sodium salt were also purchased from Sigma-Aldrich. 
All other chemicals (absolute ethanol, acetone, ethyl acetate, heptane, dry solvents, 
ammonium nitrate, etc.) were of the highest commercially available quality and used as 
received. 
GNR@MS: GNRs were prepared using a modified seeded growth method.[50] Gold 
concentration was determined from the extinction spectra using the absorbance at 400 nm.[51] 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
19 
 
Coating of Au NRs with mesoporous silica was performed following a previously described 
protocol,[33] with minor modifications. Excess reactants  were removed from the freshly 
prepared GNR solutions via two cycles of centrifugation, after which the particles were 
resuspended in 0.1 M CTAB, at a final gold concentration of 5 mM. Subsequently, 20.4  mL 
of a 6 mM CTAB solution was mixed with 60 mL of ethanol  and 134 mL of water at 30 oC in 
a 500 mL round beaker under magnetic stirring. Upon equilibration at 30 °C for 10 min, 400 
μL of NH4OH (25 vol %) was added to adjust the pH value to ca. 9. Then, 6 mL of the GNR 
solution was poured into the synthesis solution. After 5 min to ensure homogeneity of the 
solution, 160 μL of TEOS was added dropwise under vigorous stirring. The reaction mixture 
was allowed to react at 60 °C for two days. The synthesized particles were centrifuged (30 
min; 7500 rpm; 35 °C), and washed in ethanol.  
Fluorescein-labeled GNR@MS (GNR@MSF): GNR@MSF were synthesized using the same 
procedure, except that APTES-FITC (25 L) was added at low temperature (30 °C) after 5 
hours of silica growth and the temperature was then set again to 60 °C for the remaining 
reaction time (two days).  
Nanoparticles (GNR@MS, GNR@MSF, MSNF) coated with pNIPAM/NHMA (PR-NC, PR-
NCF and NCF respectively): Once GNR@MS were synthetized, the polymer layer was 
formed as described by Baeza and coworkers.[37] 40 mL of GNR@MS, GNR@MSF or MSNF 
(1.5 mg/mL) were poured in a 100 mL round-bottom flask and 0.4 mL of MPS was added in 
order to functionalize the surface with methacrylate groups where the further polymerization 
will take place (GNR@MS@MPS, GNR@MSF@MPS or MSNF@MPS). After magnetic 
stirring for 12 h at 40 oC, the mixture was washed twice by centrifugation and redispersed in 
ethanol. The surfactant template was removed by ion exchange, using an extracting solution 
comprising 1.59 g of NH4NO3, 573 mL of EtOH (99.6 %) and 27 mL of water. The mixture 
was heated up to 70 oC and stirred overnight. Then, the solution was washed twice by 
centrifugation and redispersied in ethanol. Upon surfactant extraction, polymer coating was 
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carried out following a well described protocol.[38,52] In a 100 mL three-neck round bottom 
flask, 142.5 mg (1.33 mmol) of NIPAM, 12 mg of MBA (0.078 mmol), 33.1 μL of NHMA 
(0.148 mmol), 3.6 mg of CTAB, and 5 mg of Na2CO3 were added to 45 mL of water. The 
solution was stirred under N2 bubbling at 70 °C for 30 min to remove oxygen. Meanwhile, the 
solution of NIPAM/NHMA was kept under N2, 50 mg of MPS functionalized nanocarrier was 
redispersed in 5 mL of Ethanol (99.5%) and kept under N2 bubbling for 20 min to remove 
oxygen. Then, 5 mL of MPS functionalized nanocarrier was added to the monomer solution 
and magnetically stirred for 15 min to homogenize. To initiate the monomer polymerization, 
0.2 mL of a 25 mg/mL APS solution in previously deoxygenated H2O (mQ) was added to the 
reaction mixture. Ten minutes after addition of the initiator, the reaction mixture was allowed 
to cool down to room temperature for 12 h. The mixture was centrifuged and washed twice 
with THF to remove unreacted monomers, twice with ethanol and again twice with water. 
Finally, it was dried under vacuum overnight. 
Mesoporous silica labeled with fluorescein (MSNF): Fluorescent Mesoporous Silica 
Nanoparticles (MSNF), were synthesized by a modified Stöber method, from TEOS in the 
presence of CTAB as a structure directing agent. Fluorescein-labeled nanoparticles were 
synthesized by mixing 1 mg of fluorescein isothiocyanate with 2.2 μL APTES in 50 μL 
ethanol for 2h. Then the reaction mixture was mixed with 5 mL of TEOS. In a round-bottom 
flask, 1 g of CTAB, 480 mL of H2O (Milli-Q) and 3.5 mL of NaOH (2 M) were added. The 
mixture was heated to 80 °C and gently stirred. Then, 5 mL of TEOS mixed with 52.2 L of 
the APTES-fluorescein product were added dropwise at 0.25 mL/min rate, with a pump. After 
two hours, the reaction mixture was centrifuged and washed with water and ethanol. (For 
more information about nanoparticles synthesis and functionalization, see Supporting 
Information Scheme S1 and Figures S1-S5) 
NAPamide Targeting Agent Synthesis: NAPamide synthesis was carried out through a 
conventional solid phase Fmoc/coupling methodology, previously used in our group.[53] Fmoc 
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protected amino acids were condensed to each other following the sequence Fmoc-NH-Nle-
Asp-His-D,Phe-Arg-Trp-Gly-Lys-CONH2. In this case, we used Rink amide resin to obtain an 
amide group in the acid final position, and Fmoc protected extreme amine. This analogue 
would be ready for the PEGylation step, prior to anchoring to the nanoparticle 
NIPAM/NHMA co-polymer. 
The starting Rink amide resin (1 mmol NH-Fmoc/gr x 0.3 gr) was activated by suspension in 
a DMF/piperidine 20% solution for primary amine Fmoc deprotection. After washing steps 
with DMF, the first aminoacid, (NHMtt)LysFmoc (3Eq) was condensed to the resin through a 
HBTU/HOBT/DIPEA (3Eq/3Eq/6Eq) typical coupling reaction and all the amino acids were 
deprotected and coupled until the end group, which was not unprotected. The final cleavage 
step was performed by incubation of the resin in a cocktail mixture of TFA/TIPS/H2O 
(95/2.5/2.5). The crude was afforded by precipitation of the filtered solution in cold ethyl 
ether, which was purified by flash column for molecular exclusion chromatography 
(stationary phase: Sephadex® G-25; mobile phase: water). Around 30 mg of isolated peptide 
was frozen at -80 °C and lyophilized prior to characterization (For more information about 
NAPamide synthesis, see Supporting Information Scheme S2 and Figures S6-S9). 
Targeting agent anchoring of PR-NC, PR-NCF and NCF: To a solution of (NHS)2PEG (2000 
g/mol) (11 mg, 1 mL DMF), Fmoc-protected NAPamine was added drop-wise (7 mg in 1 mL 
of DMF and 10 µL of TEA) under inert atmosphere. When the addition was finished, the 
reaction mixture was stirred overnight. The mixture was added dropwise to each nanocarrier 
previously obtained, PR-NC, PR-NCF and NCF, (12 mg) dispersion in DCM under nitrogen 
flow and the new mixture was stirred overnight. The functionalized nanoparticles were 
isolated and purified by successive washings with DCM, ethanol and water. Finally, Fmoc 
deprotection was carried out with 2mL of DMF/Piperidine solution (20%). The material was 
dried under vacuum and characterized. (See Supporting information Scheme S3) 
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Drug loading: All synthetized materials were loaded with doxorubicin hydrochloride by 
suspension of 2 mg of each material in 1 mL of ca. 5 mg/mL DOX solution in PBS. The 
suspension was stirred at 50 oC for 24 h and the nanomaterials were thoroughly washed with 
H2O 5-fold, until the typical red color from DOX disappeared from the solution. 
Internalization assay: #17 (melanoma skin cancer cells) and FF_C108 (fibroblast foreskin 
cells) were seeded in Dulbecco's modified eagle medium (DMEM) and incubated in 24-well 
plates at 40,000 cells/well, for 24 hours at 37 oC, 5% CO2 and 95% humidity. Cells were 
exposed to several concentrations of fluorescein tagged nanocarriers, for 2 hours under 
incubation conditions. 
Cells were then washed with PBS and incubated again in DMEM at the same conditions for 
24 hours. After the uptake time ended, the cells were washed again with PBS, harvested and 
treated with trypan blue. The percentage of FITC+ cells and mean fluorescence indexes (MFI) 
were obtained by flow cytometry using a FACSCanto II flow cytometer and the FACSDiva 
software v6.1.2 (BD Biosciences, San Jose, Ca.). 
Cytotoxicity in vitro assays: In order to evaluate the cytotoxicity of doxorubicin hydrochloride 
loaded on PR-NC-NAP in vitro, #17 (melanoma skin cancer cells) and FF_C108 (fibroblast 
foreskin cells) were seeded in 24-well plates at 40,000 cells/well, at 37 0C, 5% CO2 and 95% 
humidity, in DMEM. Cells were exposed to different concentrations of the loaded targeted 
nanocarrier for 2 hours and then washed with PBS to place them atincubation conditions 
again. Cell viability was determined by alamarblue® assay at various times. Percentages of 
dead cell populations are shown as the normalized mean of three independent replicates. 
 
Characterization  
UV-visible spectra were obtained using a HELIOS-ZETA UV-vis spectrophotometer. 
Transmission electron microscopy (TEM) images were obtained in a JEOL 1400 transmission 
electron microscope (TEM). The p-NIPAM/NHMA coating and the polymer plus targeting 
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samples were observed after staining the organic layer with 1% phosphotungstic acid. The 
hydrodynamic size of mesoporous nanoparticles was measured by means of a Zetasizer Nano 
ZS (Malvern Instruments) equipped with a 633 nm laser. Zeta potential was measured by a 
Zetasizer Nano ZS (Malvern Instruments). All measurements were performed in triplicate. 
FTIR spectra were measured on a Nexus spectrometer equipped with a Goldengate attenuated 
total reflectance device. Thermogravimetric analysis was performed in a Perkin Elmer Pyris 
Diamond TG/DTA analyzer, with 5 oC/min heating ramps, from room temperature to 600 oC. 
Liquid NMR experiments were made in a Bruker AV 250MHz. Mass spectra were acquired 
with a Voyager DE-STR Biospectrometry MALDI-TOF mass spectrometer. A Newport 
Diode Laser was used, with a continuous-wave NIR laser at 808 nm, the maximum fluence 
was 3 W/cm2 and the spot size 5 mm. Pre- and post-illumination temperatures of the control 
experiments were measured by a fluorooptic probe Luxtron I652. 
Abbreviations 
Mtt……protecting group methyltrityl, typical for primary amine. 
Acronyms for materials names : 
1– GNR@MS@NIPAM --------------------- PR-NC 
2– GNR@MS@NIPAM@NAPamide----- PR-NC-NAP 
3– GNR@MSF@NIPAM -------------------- PR-NCF 
4– GNR@MSF@NIPAM@NAPamide---- PR-NCF-NAP 
5– MSNF@MS@NIPAM -------------------- NCF 
6– MSNF@MS@NIPAM@NAPamide---- NCF-NAP 
 
PR: Photoresponsive 
NC: Nanocarrier 
NAPA: Napamide, targeting 
NCF: Fluorescent Nanocarrier  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
24 
 
 
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
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Core-multishell gold nanorods, coated with mesoporous silica and further covered with 
a thermosensitive polymer were  vectorized for selective internalization in melanoma 
cells. The proposed nanoformulation is capable of releasing the transported cytotoxic 
compounds on demand, in response to near-IR irradiation, with high selectivity and efficacy 
against malignant cells, even at low concentrations, thereby providing a new tool against 
melanoma disease. 
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